Iluvatar CoreX Seeks $850M Raise on China AI-Chip Rally

A Chinese GPU maker that was mostly selling to government buyers a year ago is now trying to raise about $850 million in a Hong Kong follow-on, six months after its January IPO, The Next Web reports. Iluvatar CoreX's stock has more than tripled since it listed, and this second tap of the public markets would bring the total it has drawn from public markets close to $1.3 billion.

The number that makes the raise interesting is not the $850 million but the $148 million. That is roughly what the company reported in revenue last year (about 1 billion yuan), and close to all of it came from selling GPUs. The public markets are pricing this like a national champion, but the business, on last year's numbers, is closer to a niche supplier that used to sell mostly to the government.

What has changed, according to the reporting, is a deal in talks with ByteDance for at least 50,000 chips this year, most of them for inference rather than training. That is where China's Nvidia-substitute story stops being theoretical. An inference order at that scale from a big consumer AI operator would put Iluvatar's TianGai-100, which the company pitches squarely against Nvidia's A100 and A800, into commercial-scale production workloads for the first time.

The honest caveat is that Iluvatar sits in what the piece describes as a tier-two bracket alongside Biren and Enflame, none of them yet at the scale of China's leading ASIC makers. The reporting also frames the ByteDance number as a talks-stage figure, not a signed contract, and does not break down how much of the 50,000-chip figure is committed versus aspirational. Take the specifics as reported, not settled.

The forward-looking read is straightforward. With Nvidia's best chips walled off by US export controls, Chinese buyers are casting around for anything homegrown that comes close, and Iluvatar is being handed the capital to try. Whether the tier-two label sticks depends on whether the ByteDance talks land as a real purchase order, and on what the next twelve months of revenue actually look like against a valuation that has already run.